Basal cell carcinoma is a skin cancer arising from basal cells in the epidermis. It usually grows slowly and rarely metastasizes, but can become locally destructive if not treated early.
The FDA has accepted a supplemental new drug application for aminolevulinic acid hydrochloride plus red light therapy for superficial basal cell carcinoma, with a decision date set for September 28, 2026.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07571031 |
Inter-Operator Variability in the Clinical Staging and Therapeutic Management of Basal Cell Carcinoma |
NOT_YET_RECRUITING | |
| NCT07482956 |
BCC-One-Stop-Study |
NOT_YET_RECRUITING | NA |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas |
RECRUITING | PHASE2 |
| NCT07241585 |
Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) |
NOT_YET_RECRUITING | NA |
| NCT07182240 |
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas |
RECRUITING | NA |
| NCT06624475 |
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT06600165 |
Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma |
RECRUITING | |
| NCT06598137 |
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy |
ACTIVE_NOT_RECRUITING | |
| NCT06536257 |
Personalised Immunotherapy Platform |
RECRUITING | |
| NCT06473103 |
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy |
RECRUITING | NA |
